Recent Updates
Recently added Catalysts
BLCO Positive Sentiment

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Tuesday, September 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Bausch + Lomb released a survey revealing that many women are unaware that dry eye can be a symptom of perimenopause and menopause. Only 14% of respondents recognized this association, indicating a significant awareness gap. The findings aim to inform and educate women about this often-overlooked health issue.

Market Sentiment Analysis

POSITIVE FACTORS

  • Bausch + Lomb highlights an important health issue.
  • The survey raises awareness about dry eye symptoms.
  • Encourages women to recognize health changes during menopause.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
1.4%
average across 3 past catalysts
Lead asset
Mapracorat
Phase 3 · Cataract

Full Press Release Details

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during these stages of life. According to the survey, only 14% of peri-, menopausal and p

Frequently Asked Questions

What did the Bausch + Lomb survey reveal?

The survey found that many women do not recognize dry eye as a symptom of menopause.

How many women recognized dry eye during menopause?

Only 14% of women surveyed recognized dry eye as a symptom of menopause.

What is the significance of this survey?

It highlights the awareness gap regarding dry eye symptoms in perimenopausal and menopausal women.

Who conducted the survey on dry eye awareness?

The survey was conducted by Bausch + Lomb Corporation.

ShareAdd on Google
Tags: BLCO Viatris Investor Conferences Healthcare Bausch + Lomb dry eye menopause perimenopause women's health
Last updated: Sep 1, 2026

Biotech snapshot

Cash runway
$378M liquidity · $0M/mo burn
Low dilution risk
Lead asset
MapracoratPhase 3
Cataract →

Catalyst track record

+13%
best trade around BLCO's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for BLCO.

See every catalyst's timing & PoA →